Literature DB >> 12084223

Gene therapy for urologic cancer.

Fernando A Ferrer1, Ronald Rodriguez.   

Abstract

Advances in molecular technology and the completion of the human genome project have ushered in a new era of medicine, that of gene therapy. In every field of medicine, investigators are developing gene therapeutics in an attempt to cure diseases. Urologic oncology is no exception. Herein, we review the current status of gene therapy for urologic malignancy. Included is an overview of advances in gene delivery systems and immunology, which are driving forces for gene therapy research. Finally, we review the current gene therapy trials and experimental approaches for urologic malignancy.

Entities:  

Mesh:

Year:  2002        PMID: 12084223     DOI: 10.1007/s11934-002-0014-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  42 in total

1.  Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture.

Authors:  W P ROWE; R J HUEBNER; L K GILMORE; R H PARROTT; T G WARD
Journal:  Proc Soc Exp Biol Med       Date:  1953-12

2.  Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate.

Authors:  C T Lee; J Y Seol; K H Park; C G Yoo; Y W Kim; C Ahn; Y W Song; S K Han; J S Han; S Kim; J S Lee; Y S Shim
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

3.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  High efficiencies of gene transfer with immobilized recombinant retrovirus: kinetics and optimization.

Authors:  B Bajaj; P Lei; S T Andreadis
Journal:  Biotechnol Prog       Date:  2001 Jul-Aug

5.  Dendritic cell-based immunotherapy of prostate cancer.

Authors:  M L Salgaller; B A Tjoa; P A Lodge; H Ragde; G Kenny; A Boynton; G P Murphy
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

6.  Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons.

Authors:  J Fleming; S L Ginn; R P Weinberger; T N Trahair; J A Smythe; I E Alexander
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695

Review 7.  Gene transfer: a review of methods and applications.

Authors:  H M Prince
Journal:  Pathology       Date:  1998-11       Impact factor: 5.306

8.  Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.

Authors:  F Chen; T Kishida; F M Duh; P Renbaum; M L Orcutt; L Schmidt; B Zbar
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

9.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy.

Authors:  Y Li; R C Pong; J M Bergelson; M C Hall; A I Sagalowsky; C P Tseng; Z Wang; J T Hsieh
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

10.  Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.

Authors:  S A Rosenberg
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.